Holen Sie sich die Stockscreener-App
48.85
1.49%
-0.74
Vorhandelsmarkt:
48.80
-0.05
-0.10%
Schlusskurs vom Vortag:
$49.59
Offen:
$49.38
24-Stunden-Volumen:
1.12M
Relative Volume:
0.99
Marktkapitalisierung:
$3.88B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-8.2239
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
+1.41%
1M Leistung:
+2.56%
6M Leistung:
-3.04%
1J Leistung:
+42.05%
1-Tages-Spanne:
$48.09
$49.99
1-Wochen-Bereich:
$47.35
$54.24
52-Wochen-Spanne:
$30.41
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
48.85 | 3.96B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst (NASDAQ:PTCT) - Seeking Alpha
Morgan Stanley lowers PT for PTC Therapeutics to $71 from $76. - AInvest
RBC says PTC Therapeutics CRL may signal difficulty for Biohaven - Yahoo Finance
PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital - Yahoo Finance
Charles Schwab Investment Management Inc. Cuts Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics' (NASDAQ:PTCT) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
FDA slaps CRL on PTC Therapeutics’ vatiquinone NDA - The Pharma Letter
PTC stung by FDA decision not to approve rare disease drug - pharmaphorum
PTC’s vatiquinone approval hopes dashed in Friedreich’s Ataxia - Yahoo Finance
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided - MSN
PTC Therapeutics, Inc. $PTCT Shares Sold by US Bancorp DE - MarketBeat
PTC Therapeutics, Inc. $PTCT Position Increased by Sector Gamma AS - MarketBeat
Nuveen LLC Acquires Shares of 1,009,168 PTC Therapeutics, Inc. $PTCT - MarketBeat
US FDA declines to approve PTC Therapeutics’ rare genetic disorder drug - WKZO
Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection - insights.citeline.com
PTC Therapeutics stock falls as FDA issues CRL for vatiquinone in FA - Investing.com Canada
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
PTC Therapeutics stock price target lowered to $63 at Jefferies on FDA rejection - Investing.com
PTC Therapeutics Surges on Q2 Earnings and Strategic Moves - StocksToTrade
US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder - Reuters
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns - inkl
100,000 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Public Sector Pension Investment Board - MarketBeat
US FDA declines to approve PTC Therapeutics' rare genetic disorder drug - Reuters
FDA rejects PTC’s Friedreich’s ataxia drug - Endpoints News
PTC Therapeutics Receives FDA Complete Response Letter - MSN
PTC Therapeutics rare disease therapy rejected (PTCT:NASDAQ) - Seeking Alpha
PTC Therapeutics stock falls after FDA rejects vatiquinone application - Investing.com
PTC Therapeutics Says FDA Issues CRL For Vatiquinone NDA In Friedreich's Ataxia - Nasdaq
Ptc Therapeutics receives complete response letter for Vatiquinone NDA - MarketScreener
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA | PTCT Stock News - GuruFocus
PTC Therapeutics and the FDA's August 19, 2025 PDUFA Deadline for Vatiquinone: Navigating Risk and Reward in Orphan Drug Development - AInvest
FDA Denies Approval: PTC Therapeutics' Vatiquinone for Rare Genetic Disease Friedreich's Ataxia Hits Setback - Stock Titan
PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds - Yahoo Finance
Is PTC Therapeutics Inc. stock a good dividend stockJuly 2025 Momentum & High Win Rate Trade Alerts - theviewers.co.kr
PTC Therapeutics, Inc. $PTCT Holdings Raised by Deutsche Bank AG - MarketBeat
PTC Therapeutics Gains FDA Approval for Sephience - MSN
Vanguard Group Inc. Has $438.63 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript - MSN
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $69.85 - MarketBeat
Leerink Partnrs Predicts Lower Earnings for PTC Therapeutics - MarketBeat
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com South Africa
Behind the Scenes of PTC Therapeutics's Latest Options Trends - Benzinga
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by Wall Street Zen - MarketBeat
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Ptc Therapeutics, Inc. shares rise 6.59% intraday after presenting at Oppenheimer 28th Annual Tech Conference. - AInvest
PTC Therapeutics: Stock Rises Amid Mixed Signals - TipRanks
Phenylketonuria Market to Witness Promising Upswing by 2034, - openPR.com
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
RBC Capital Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $63 - 富途牛牛
PTC Therapeutics’ Earnings Call Highlights Sephience Success - MSN
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO |
Aug 15 '25 |
Sale |
48.58 |
2,813 |
136,656 |
103,901 |
2.44%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):